sodium-glucose cotransporter 2
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
... Selective sodium glucose cotransporter-2 (SGLT2) inhibitors were extensively studied in type 2 DM and found to have sustained urinary glucose loss, improvement of glycemic ...
7
Mechanism Underlying Increase of the Serum Magnesium Concentration Observed Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors
... the sodium-glucose cotransporter 2 inhibitor (SGLT2-i) suppressed cardiovascular (CV) events in patients with type 2 diabetes; we recently suggested that increase of the serum magnesium ...
8
Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
... type 2 diabetes mellitus is the risk of adverse cardiovascular ...the sodium-glucose cotransporter 2 inhibitor empagliflozin in type 2 diabetic patients at high risk of ...
9
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
... type 2 diabetes, novel uses, cardiovascular bene fi ts, side effects and contraindications of sodium-glucose cotransporter-2 (SGLT2) ...blood glucose levels, but it is important ...
12
The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study
... Objective To investigate the change of chronic diabetic macular oedema (DMO) in vitrectomised eyes when the administration of sodium–glucose cotransporter 2 (SGLT2) inhibitors is initiated as ...
6
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
... type 2 diabetes mel- litus (T2DM), many patients do not achieve glycemic ...the sodium-glucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves ...
13
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
... cotransporter 2 (SGLT2) inhibitor empagliflozin, has generated great interest among health care ...of Sodium-Glucose Cotransporter-2 Inhibitors (CVD-REAL), which compared SGLT2 ...
16
SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2), A NEW APPROACH IN TYPE 2 DIABETES MELLITUS TREATMENT
... glucose reabsorption in the kidneys and some neurotransmitter dysfunction, are also involved in the pathophysiology of T2DM. [1] The currently available antidiabetic agents have been developed to target one or ...
11
Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
... [1–3]. Sodium glucose cotransporter 2 (SGLT2) inhibitors have newly emerged as an anti-hyperglycemic drug for type 2 dia- betes mellitus (T2DM) by inhibiting glucose and ...
6
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
... concentration of the analyte in plasma; CV [%]: Coefficient of variance; CVD: Cardiovascular disease; ECG: Electrocardiogram; HEK293 cells: Human embryonic kidney cells; hERG: Human ether-a-go-go related gene; HPLC-MS/ ...
11
In-Vitro Antioxidant Activity and Free Radical Scavenging Potential of Phlorizin Derived Sodium Glucose Cotransporter 2 Inhibitor
... modification for the assessment of extent of inhibition of lipid peroxidation using egg yolk homogenate as lipid rich media. 500 μl of 10% egg yolk homogenate was added to tubes containing 100 μl of drug solution of ...
8
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
... type 2 diabetes at high cardiovascular risk [10] and signifi- cantly reduced onset or worsening of nephropathy in subgroup analysis ...type 2 diabetes at high risk ...
10
The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes Management
... type 2 diabetes, both in drug- naive patients with a short duration of disease and in those with a long history of type 2 diabetes who are receiving insulin ...of glucose to the proximal tubule, they ...
5
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
... Full-text randomized trials published in English and con- ducted on T2DM patients .18 years old were eligible. It was required that articles should have assessed the efficacy and safety of SGLT2 inhibitors ...
19
Metabolic response to sodium glucose cotransporter 2 inhibition in type 2 diabetic patients
... oral glucose (or, presumably, gastric emptying) but results in a compensatory increase in endogenous glucose release and lower tissue glucose uptake as a consequence of lower glucose and ...
11
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
... Genetic mutations leading to renal glucosuria support the long-term safety of SGLT2 inhibition in humans. However, the long-term efficacy and safety of these drugs in patients with type 2 diabetes remains to be ...
15
Oral Pharmacotherapy for Patients with Diabetic Kidney Disease: An Update
... DKD. Sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin, canagliflozin, and empagliflozin) and certain dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, alogliptin, and ...
6
REVIEW ONPHARMACOKINETICS OF EMPAGLIFLOZIN, AN INHIBITOR OF THE SODIUM GLUCOSE CO TRANSPORTER 2 (SGLT 2)
... the sodium-glucose cotransporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephrotic components in the ...of glucose reabsorption into the blood. ...
7
Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
... the sodium-glucose cotransporter 2 (SGLT2) inhibi- tors, some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have also demonstrated a marked risk reduction in major adverse CV events ...
6
SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
... type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy ...and sodium–glucose cotransporter 2 ...versus sodium–glucose ...
11